piperidine/vomiting

This application is a 371 of PCT/JP96/00796 filed Mar. 27, 1996. TECHNICAL FIELD The present invention relates to new piperidine derivatives having an antagonism on Substance P, being a peptide neurotransmitter, and pharmaceutically acceptable acid addition salts thereof. The piperidine derivatives

The present invention relates to certain benzoamide piperidine containing compounds and related compounds that exhibit activity as NK-1 receptor antagonists, (e.g., substance P receptor antagonists), to pharmaceutical compositions containing them, and to their use in the treatment and prevention of

SUMMARY OF THE INVENTION According to one aspect of our invention, we provide compounds of the general formula ##STR1## wherein R represents a halogen atom or a hydroxy, lower alkoxy, lower alkenyloxy, lower alkynyloxy or aralkyloxy (preferably a phenyl(lower)alkyloxy, e.g. benzyloxy) group, or a

BACKGROUND OF THE INVENTION Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in

BACKGROUND OF THE INVENTION Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in

BACKGROUND OF THE INVENTION Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in

BACKGROUND OF THE INVENTION The present invention relates to a method of treating or preventing emesis in mammals, including humans, using certain quinuclidine derivatives, piperidine derivatives, azanorbornane derivatives, ethylene diamine derivatives and related compounds. The pharmaceutically

FIELD OF THE INVENTION This invention relates to piperidine derivatives, to processes for their preparation and to pharmaceutical compositions comprising them. In particular the invention relates to compounds which are selective antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3

DETAILED DESCRIPTION OF THE INVENTION The invention relates to novel N-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-4-(quinoloylamino)-piperidin- es of the formula ##STR00002## wherein Y is .dbd.N-- or .dbd.N(O)--, R is OH when Y is .dbd.N-- and R is H when Y is .dbd.N(O)-- and the ring A is

This invention relates to a class of azacyclic compounds which are useful as tachykinin antagonists. More particularly, the compounds of the invention are spiro-substituted azacyclic derivatives. The tachykinins are a group of naturally occurring peptides found widely distributed throughout

BACKGROUND OF THE INVENTION Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in

BACKGROUND OF THE INVENTION Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in

BACKGROUND OF THE INVENTION Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in

This invention relates to a class of heterocyclic compounds, which are useful as tachykinin receptor antagonists. The tachykinins are a group of naturally occurring peptides found widely distributed throughout mammalian tissues, both within the central nervous system and in peripheral nervous and

This application claims priority from PCT/GB97/01630, filed Jun. 17, 1997, now WO97/49710 published Dec. 31, 1997 which claims priority under from Great Britain Application No. 9613108.1, filed Jun. 21, 1996, Great Britain Application No. 9625051.9 filed Dec. 2, 1996, Great Britain Application No.